China’s Antengene raises $120m Series B round
Antengene Corporation, a Chinese biopharmaceutical company focused on oncology drugs and therapies, has raised $120 million in a Series B round led by Boyu Capital and FountainVest Partners.
Other participants include Celgene Corporation, WuXi Corporate Venture Fund, Taikang Insurance Group, and existing investors Qiming Venture Partners and TF Capital. The company raised a $21 million Series...
More on Greater China
Latest News
Deal focus: Reworld turns gamers into creators
China's Reworld has a technology that lowers barriers to entry in online game design, allowing anyone to become a creator. Joy Capital is backing the company to take user-generated content to another level
PE-backed Chinese pop toy retailer pursues Hong Kong IPO
Pop Mart International Group, China’s largest fashion toy retailer, has filed for a Hong Kong IPO. Sequoia Capital China, Loyal Valley Capital and Huaxing Growth Fund are its three largest institutional backers.
Singapore fintech launches SME exchange in Cambodia
PLMP Venture Capital (PLMP VC), an investor affiliated with a Singaporean financial technology firm, has launched a local exchange for small and medium-sized enterprises (SMEs) in Cambodia.
India’s Iron Pillar sells GP stake to US investor
Indian venture capital player Iron Pillar Capital Management has brought in US-headquartered real estate investment firm Nitya Capital as a strategic investor.